Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

STERIS plc Stock Research

STE

217.82USD-5.41(-2.42%)Market Closed
Watchlist

Market Summary

USD217.82-5.41
Market Closed
-2.42%

STE Stock Price

STE RSI Chart

STE Valuation

Market Cap

22.1B

Price/Earnings (Trailing)

184.8

Price/Sales (Trailing)

4.34

EV/EBITDA

25.7

Price/Free Cashflow

44.67

STE Price/Sales (Trailing)

STE Profitability

Operating Margin

45.03%

EBT Margin

3.17%

Return on Equity

1.76%

Return on Assets

0.99%

Free Cashflow Yield

2.24%

STE Fundamentals

STE Revenue

Revenue (TTM)

5.1B

Revenue Y/Y

11.07%

Revenue Q/Q

-7.24%

STE Earnings

Earnings (TTM)

119.3M

Earnings Y/Y

11.05%

Earnings Q/Q

-34.01%

Price Action

52 Week Range

158.76254.00
(Low)(High)

Last 7 days

-1.6%

Last 30 days

-1.4%

Last 90 days

2.9%

Trailing 12 Months

36.4%

STE Financial Health

Current Ratio

2.33

STE Investor Care

Dividend Yield

0.84%

Dividend/Share (TTM)

1.88

Buy Backs (1Y)

1.31%

Diluted EPS (TTM)

1.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for STE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-06-02
Madsen Julia
sold (taxes)
-50,751
205
-247
senior vp, life sciences
2023-06-02
Burton Karen L
sold (taxes)
-26,094
205
-127
vp, controller & cao
2023-06-02
Carestio Daniel A
sold (taxes)
-497,648
205
-2,422
president and ceo
2023-06-02
Zangerle John Adam
sold (taxes)
-102,324
205
-498
sr. vp, gen counsel, and sec.
2023-06-02
Xilas Andrew
sold (taxes)
-21,163
205
-103
svp and gm, dental
2023-06-01
Carestio Daniel A
sold (taxes)
-301,808
202
-1,491
president and ceo
2023-06-01
Madsen Julia
sold (taxes)
-8,704
202
-43.00
senior vp, life sciences
2023-06-01
Burton Karen L
sold (taxes)
-12,145
202
-60.00
vp, controller & cao
2023-06-01
Zangerle John Adam
sold (taxes)
-45,544
202
-225
sr. vp, gen counsel, and sec.
2023-06-01
Fraser Mary Clare
sold (taxes)
-47,771
202
-236
svp & chief hro

1–10 of 50

Which funds bought or sold STE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
added
152
20,138,000
30,354,000
0.02%
2023-09-12
Farther Finance Advisors, LLC
added
58.29
28,870
62,355
0.01%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
unchanged
-
1,247
8,324
-%
2023-09-01
Portside Wealth Group, LLC
new
-
591,255
591,255
0.11%
2023-08-28
DT Investment Partners, LLC
unchanged
-
1,850
12,993
-%
2023-08-22
Asset Dedication, LLC
reduced
-2.49
9,000
71,000
0.01%
2023-08-21
BOKF, NA
unchanged
-
101
675
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-4.32
1,078,460
9,841,200
0.02%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-1.98
4,799,520
36,187,800
0.05%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-1.69
272,000
2,014,000
0.02%

1–10 of 47

Latest Funds Activity

Are funds buying STE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own STE
No. of Funds

Schedule 13G FIlings of STERIS

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
wcm investment management, llc
5.6%
5,563,771
SC 13G/A
Feb 09, 2023
vanguard group inc
11.99%
11,966,040
SC 13G/A
Feb 08, 2023
blackrock inc.
8.7%
8,710,879
SC 13G
Feb 08, 2023
massachusetts financial services co /ma/
5.0%
5,038,403
SC 13G
Feb 03, 2022
blackrock inc.
8.1%
8,128,575
SC 13G/A
Feb 11, 2021
janus henderson group plc
3.8%
3,253,302
SC 13G/A
Feb 10, 2021
vanguard group inc
10.58%
9,025,143
SC 13G/A
Feb 01, 2021
blackrock inc.
9.0%
7,688,347
SC 13G/A
Feb 13, 2020
janus henderson group plc
6.5%
5,482,611
SC 13G/A
Feb 06, 2020
blackrock inc.
8.7%
7,337,284
SC 13G

Recent SEC filings of STERIS

View All Filings
Date Filed Form Type Document
Aug 08, 2023
10-Q
Quarterly Report
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading

Peers (Alternatives to STERIS)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
105.0B
31.6B
-3.94% -2.93%
28.96
3.33
1.57% -30.40%
103.9B
19.5B
-1.64% 35.04%
38.34
5.34
10.36% 30.30%
102.1B
6.7B
-2.29% 54.71%
71.68
15.33
11.75% -0.66%
71.3B
19.0B
-6.81% 13.51%
44.09
3.79
0.46% -5.24%
42.8B
5.7B
-7.61% -15.82%
30.79
7.56
5.64% -4.53%
MID-CAP
9.4B
937.8M
-2.31% 34.57%
323.13
10.04
16.30% 250.21%
7.2B
616.6M
-8.54% -23.02%
29.49
11.66
69.52% 343.68%
5.0B
1.1B
-9.61% -15.17%
23.63
4.53
12.63% 50.85%
2.6B
452.1M
-18.56% -28.66%
-26.15
5.74
24.99% 24.09%
1.4B
790.3M
-22.43% -53.70%
-6.08
1.73
3.21% -1604.53%
SMALL-CAP
953.5M
780.7M
-5.52% -6.22%
-26.49
1.22
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
608.6M
162.9M
-22.30% -62.37%
-11.51
3.74
42.67% 12.82%
596.0M
162.2M
25.64% -36.45%
-7.09
3.67
9.71% 12.37%

STERIS News

Best Stocks
HighNetWorth Traders Divided on Strykers Outlook.
Best Stocks,
99 minutes ago
Investor's Business Daily
Investing.com México
Yahoo Finance
InvestorsObserver

Returns for STE

Cumulative Returns on STE

19.0%


10-Year Cumulative Returns

18.4%


7-Year Cumulative Returns

15.4%


5-Year Cumulative Returns

10.2%


3-Year Cumulative Returns

Risks for STE

What is the probability of a big loss on STE?

43.9%


Probability that STERIS stock will be more than 20% underwater in next one year

31.9%


Probability that STERIS stock will be more than 30% underwater in next one year.

0%


Probability that STERIS stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does STE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if STERIS was unfortunately bought at previous high price.

Drawdowns

Financials for STERIS

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue2.6%5,0864,9584,7844,7774,7734,5854,2483,8483,4073,1083,0573,0223,0033,0312,9762,8982,8402,7822,7302,6962,043
Gross Profit2.6%2,2152,1602,1432,1602,1082,0161,8251,6321,4821,3431,3261,3121,3001,3201,2921,2471,2131,1751,1331,124850
Operating Expenses1.3%1,9171,8922,0092,0131,5381,5911,3471,2101,035795765756759783770799785764760705699
  S&GA Expenses1.9%1,3231,2991,4171,4221,4441,5031,2701,142970731699690693717701704690670662641634
  R&D Expenses0.7%10210210110195.0088.0079.0071.0068.0066.0066.0066.0066.0066.0064.0063.0062.0063.0063.0064.0065.00
EBITDA-100.0%-8187777731,177957837719685774776764744736722------
EBITDA Margin-100.0%-0.17*0.16*0.16*0.25*0.21*0.20*0.19*0.20*0.25*0.25*0.25*0.25*0.24*0.24*------
Interest Expenses9.0%11810899.0094.0090.0090.0078.0064.0050.0037.0037.0038.0039.0040.0042.0043.0044.0045.0045.0046.0047.00
Earnings Before Taxes14.6%18015734.0056.00478315379336380518530524508499484407385369315357332
EBT Margin-100.0%-0.03*0.01*0.01*0.10*0.07*0.09*0.09*0.11*0.17*0.17*0.17*0.17*0.16*0.16*------
Net Income11.5%119107-27.93-8.14377244279250286397433423412408394337319304269316245
Net Income Margin-100.0%-0.02*-0.01*0.00*0.08*0.05*0.07*0.06*0.08*0.13*0.14*0.14*0.14*0.13*0.13*------
Free Cashflow-100.0%-395349399472397412400424450476400384376340------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q1
Assets-0.3%10,78410,82210,80010,49011,18811,42411,69011,75212,1016,5746,5815,4935,3645,4415,3365,1865,2305,0735,200
  Current Assets1.0%2,0312,0111,9771,8881,8481,8791,9271,9052,0081,2121,1761,1501,0971,2241,0531,0321,0441,054990
    Cash Equivalents0.1%209208259258316348359383535221253312256320199226238221202
  Inventory10.5%769695694645620575595565593315294279277264252237234208206
  Net PPE1.2%1,7261,7061,6711,5721,5731,5531,5221,5111,4991,2351,2271,1761,1481,1121,1031,0661,0541,0321,011
  Goodwill0.2%3,8873,8793,8533,7054,3214,4045,1155,1335,2873,0262,9272,4182,3722,3562,4042,3192,3472,3232,434
Liabilities-2.7%4,6064,7354,7514,6764,7694,8795,0665,2085,5162,6832,7031,8301,8742,0231,9401,9481,9851,8871,983
  Current Liabilities2.9%8878627968739089229047861,145578506435480504451428433465398
  Short Term Borrowings5.7%63.0060.0060.0015115114312822.007.00---35.00------
    LT Debt, Non Current-5.3%2,8603,0193,0022,8742,8462,9453,1753,4223,2571,6511,7131,0211,0221,1511,1371,1871,2101,1831,316
Shareholder's Equity1.5%6,1686,0776,0385,8136,4196,5456,6246,5456,5853,8913,8913,6753,5033,4183,3963,2383,2453,1973,217
  Retained Earnings3.6%1,9811,9121,7711,6952,0571,9991,9901,8931,8751,9391,8731,7871,7001,6591,5441,4731,3971,3391,146
Shares Outstanding0.2%99.0099.0099.0010010010010010010085.0085.0085.0085.0085.0085.0085.0085.0085.0085.00
Minority Interest1.1%10.0010.0010.0011.0012.0012.0012.009.0010.0010.0011.0015.0015.0013.0013.009.008.008.0011.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations6.5%806757713752819685701662653690701627615591570573548540481453403
  Share Based Compensation6.7%42.0039.0040.0040.0040.0058.0054.0050.0047.0026.0025.0024.0024.0024.0024.0024.0024.0024.0024.0026.0021.00
Cashflow From Investing11.2%-340-383-212-193-172-666-878-1,721-1,690-1,154-1,095-247-302-319-333-330-262-213-186-136-139
Cashflow From Financing-14.5%-570-498-581-650-8441162941,1251,298346433-298-289-163-264-218-263-294-245-279-156
  Dividend Payments1.9%187183180176172163154145137134131128126123120118115113112110105
  Buy Backs-5.2%29330918210170.0056.0028.0025.0011.0015.0025.0028.0051.0051.0066.0063.0063.0081.0075.00112135

STE Income Statement

2023-06-30
CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Revenues:  
Revenues$ 1,284,542$ 1,156,491
Cost of revenues:  
Total cost of revenues711,081638,693
Gross Profit573,461517,798
Operating expenses:  
Selling, general, and administrative359,058334,626
Research and development25,50224,751
Restructuring Costs1926
Total operating expenses384,579359,403
Income from operations188,882158,395
Non-operating expenses, net:  
Interest expense32,36122,674
Interest income and miscellaneous expense(1,393)770
Total non-operating expenses, net30,96823,444
Income before income tax expense157,914134,951
Income tax expense34,12424,196
Net Income123,790110,755
Less: Net Income Attributable to Noncontrolling Interest236(507)
Net Income (Loss) Attributable to Shareholders$ 123,554$ 111,262
Net income per common share [Abstract]  
Basic$ 1.25$ 1.11
Diluted1.251.10
Cash dividends declared per common share outstanding$ 0.47$ 0.43
Product [Member]  
Revenues:  
Revenues$ 713,858$ 637,076
Cost of revenues:  
Cost of Goods and Services Sold377,178332,855
Service [Member]  
Revenues:  
Revenues570,684519,415
Cost of revenues:  
Cost of Goods and Services Sold$ 333,903$ 305,838

STE Balance Sheet

2023-06-30
CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Mar. 31, 2023
Current assets:  
Cash and cash equivalents$ 208,614$ 208,357
Accounts receivable (net of allowances of $24,367 and $23,427, respectively)887,756928,315
Inventories, net768,835695,493
Prepaid expenses and other current assets166,050179,277
Total current assets2,031,2552,011,442
Property, plant, and equipment, net1,726,0911,705,512
Operating Lease, Right-of-Use Asset195,292191,741
Goodwill3,886,5993,879,219
Intangible Assets, Net (Excluding Goodwill)2,865,1072,955,780
Other assets80,03678,145
Total assets10,784,38010,821,839
Current liabilities:  
Accounts payable260,687279,620
Accrued income taxes63,50143,804
Accrued payroll and other related liabilities132,112125,642
Capital Lease Obligations, Current34,41334,961
Short-term Debt63,43860,000
Accrued expenses and other332,760317,817
Total current liabilities886,911861,844
Long-term indebtedness2,860,1163,018,655
Deferred Income Taxes and Other Tax Liabilities, Noncurrent617,633617,538
Capital Lease Obligations, Noncurrent164,744160,493
Other Liabilities, Noncurrent76,60476,137
Total liabilities4,606,0084,734,667
Commitments and contingencies (see Note 8)
Common shares, with $0.001 par value; 500,000 authorized; 98,781 shares issued; and 98,629 shares outstanding, respectively.4,498,2124,486,375
Retained earnings1,980,9331,911,533
Accumulated other comprehensive income(310,859)(320,710)
Total shareholders' equity6,168,2866,077,198
Noncontrolling interest10,0869,974
Total equity6,178,3726,087,172
Total liabilities and equity$ 10,784,380$ 10,821,839
Daniel A. Carestio
13000
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company was founded in 1985 and is based in Dublin, Ireland.